News Column

Avacta Group Launches New OPTIM Variants As It seeks new Customers

August 4, 2014

Steve McGrath

LONDON (Alliance News) - Diagnostic tools and reagents company Avacta Group PLC Monday said its analytical business had completed developing two new variants of its protein characterisation instrument OPTIM and launched new software for the device, a move it hopes with widen the range of potential customers in the drug development market.

The two new variants to the OPTIM platform, OPTIM 375 and OPTIM 445, incorporate incremental measurement capabilities, it said.

"The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples," Chief Executive Alastair Smith said in a statement.

Avacta shares were down 5.4% at 0.885 pence Monday morning.

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Alliance News

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters